Evercore ISI Begins Coverage on Alnylam Pharmaceuticals (ALNY)

Evercore ISI began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note published on Thursday, April 11th, Stock Target Advisor reports. The brokerage issued an outperform rating and a $120.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on the company. Leerink Swann upped their target price on Alnylam Pharmaceuticals to $90.00 and gave the company a market perform rating in a research note on Tuesday, April 9th. Zacks Investment Research lowered Alnylam Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, April 9th. Svb Leerink increased their price target on Alnylam Pharmaceuticals from $65.00 to $70.00 and gave the stock a market perform rating in a research note on Tuesday, April 9th. BMO Capital Markets increased their price target on Alnylam Pharmaceuticals from $106.00 to $119.00 and gave the stock an outperform rating in a research note on Tuesday, April 9th. Finally, Cantor Fitzgerald reissued a buy rating and set a $135.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of Buy and an average price target of $128.72.

ALNY opened at $77.29 on Thursday. The company has a quick ratio of 6.56, a current ratio of 6.69 and a debt-to-equity ratio of 0.02. The company has a market cap of $8.22 billion, a price-to-earnings ratio of -10.21 and a beta of 2.53. Alnylam Pharmaceuticals has a 52 week low of $60.27 and a 52 week high of $124.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative return on equity of 50.82% and a negative net margin of 1,016.58%. The company had revenue of $33.29 million for the quarter, compared to analysts’ expectations of $21.60 million. During the same quarter in the previous year, the firm posted ($1.22) EPS. The firm’s quarterly revenue was up 52.0% on a year-over-year basis. On average, equities research analysts expect that Alnylam Pharmaceuticals will post -8.68 earnings per share for the current fiscal year.

In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $88.23, for a total value of $1,323,450.00. Following the transaction, the director now directly owns 250,633 shares of the company’s stock, valued at $22,113,349.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.60% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC boosted its holdings in Alnylam Pharmaceuticals by 97.4% in the 3rd quarter. SG Americas Securities LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $825,000 after acquiring an additional 4,652 shares during the period. Panagora Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 31.4% in the 3rd quarter. Panagora Asset Management Inc. now owns 4,094 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 979 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Alnylam Pharmaceuticals by 768.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,294 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,145 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its position in shares of Alnylam Pharmaceuticals by 55.2% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 3,724 shares of the biopharmaceutical company’s stock worth $326,000 after purchasing an additional 1,324 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Alnylam Pharmaceuticals by 6,519.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 213,065 shares of the biopharmaceutical company’s stock worth $18,648,000 after purchasing an additional 209,846 shares during the last quarter. Institutional investors and hedge funds own 86.91% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Story: What is intrinsic value?

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.